TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16265778
Drug: 6-IP (omega-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-IP (omega-6 fatty acid, 9 g/day)
Study: 16265778
Drug: Control (prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (prednisolone 40 mg for 1 week, tapering by 5 mg/week)
Study: 8634560
Drug: Albendazole 800
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole 800 mg twice daily for two weeks
Study: 2054264
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (300 mg)
Study: 2054264
Drug: Ferrous gluconate
Normalized name: Ferrous Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous gluconate (600 mg)
Study: 2054264
Drug: Centrum Forte
Normalized name: Erythroped Forte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centrum Forte (combination tablet)
Study: 31370976
Drug: Usual dose
Normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual dose of buprenorphine (100%)
Study: 31370976
Drug: 150% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150% of usual daily dose of buprenorphine
Study: 31370976
Drug: 200% of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200% of usual daily dose of buprenorphine
Study: 22261849
Drug: Endoscopic CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic CO(2) laser resections combined with mitomycin‐C and/or triamcinolone acetonide therapy
Study: 22261849
Drug: Long‐term oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long‐term oral steroid and immunosuppressive therapy as well as the use of proton pump inhibitors
Study: 10401941
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg q.i.d. for 3 days)
Study: 7722951
Drug: Body temperature
Normalized name: NITRIC OXIDE 400 mg in 500 mg TOPICAL CAPSULE [Bio NO Brain Care (Helps improve Brain blood flow and body temperature, Fermented Garlic powder)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body temperature measurement sites (bladder, oral cavity, rectum, tympanic membrane)
Study: 2327747
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 g every 12 h for four doses) with Tobramycin (2 mg/kg)
Study: 2327747
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 g every 12 h for four doses) with Netilmicin (2 mg/kg)
Study: 2327747
Drug: Piperacillin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (4 g single dose)
Study: 31362773
Drug: Low-carbohydrate/high-protein (LC/HP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-carbohydrate/high-protein (LC/HP) dietary intervention (30% total energy as protein, 1.6 g/kg per day, carbohydrate-to-protein ratio < 1.5, fat intake at 30% of total energy)
Study: 31362773
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dietary intervention, regular daily diets)
Study: 29937536
Drug: Enteric tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric tablets with high-protein meal
Study: 29937536
Drug: Non-enteric tablets
Normalized name: diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-enteric tablets
Study: 29937536
Drug: Garlic powder
Normalized name: Garlic Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic powder capsules
Study: 29937536
Drug: Kwai garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kwai garlic powder tablets
Study: 19942722
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (n = 4)
Study: 10412777
Drug: Short-term intensive
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term intensive therapy (SIT)
Study: 10412777
Drug: Long-term intermittent
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term intermittent therapy (LIT)
Study: 6456668
Drug: Intravenous mezlocillin
Normalized name: mezlocillin
DrugBank: Mezlocillin (DB00948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous mezlocillin (16 gm/day)
Study: 26938333
Drug: Cilostazol 100
Normalized name: cilostazol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilostazol 100 mg taken twice daily (n = 48)
Study: 26938333
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 100 mg daily (n = 41)
Study: 21820247
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 75-150 μg/d administration
Study: 20163267
Drug: Alternative systemic
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative systemic agents to first‐line antimonials
Study: 20163267
Drug: Enhanced topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced topical paromomycin preparation
Study: 20163267
Drug: Immunotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy and immunomodulators
Study: 20163267
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro studies of several drugs
Study: 28762878
Drug: Pitavastatin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (4 mg daily)
Study: 20927415
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (conventional treatment with RMGIC)
Study: 18485043
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine, fluoxetine, and sertraline
Study: 18485043
Drug: Phosphodiesterase-5 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phosphodiesterase-5 inhibitors
Study: 18485043
Drug: Topical anaesthetics
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetics
Study: 18485043
Drug: Tramadol (narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (narcotic analgesic)
Study: 15747269
Drug: Remifentanil (0.10‐0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.10‐0.25 microg/kg/min) with spinal morphine (4 microg/kg) and clonidine (1 microg/kg)
Study: 15747269
Drug: Sufentanil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil (up to 3.5 microg/kg) with patient-controlled administration of intravenous morphine
Study: 9747741
Drug: Bisphosphonate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate treatment in patients with severe hypercalcaemia (n=51, all treated except one).
Study: 9747741
Drug: No bisphosphonate
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bisphosphonate treatment in patients with severe hypercalcaemia (period 1).
Study: 8605517
Drug: 3.5‐day dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5‐day dietary multibuffer supplement (PhosFuel)
Study: 788743
Drug: L-noradrenaline infusion
Normalized name: L-noradrenaline
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-noradrenaline infusion
Study: 29055668
Drug: Single isocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single isocaloric liquid meal (L-SM) 600-kcal
Study: 15099277
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0-2.5)
Study: 15099277
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.8-4.2)
Study: 15099277
Drug: Aspirin 160
Normalized name: aspirin 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 160 mg d(‐1)
Study: 15099277
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg d(‐1)
Study: 15099277
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (Aspirin + Warfarin)
Study: 9803197
Drug: Antihypertensive drug
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive drug therapy (diuretics or beta-adrenergic blockers)
Study: 30653851
Drug: Spironolactone/Pioglitazone/Metformin (SPIOMET),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone/Pioglitazone/Metformin (SPIOMET), n = 24
Study: 30653851
Drug: Oral Contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Contraceptive (OC), n = 27
Study: 24969566
Drug: 16 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 g/day Inulin-type fructans (ITF) for 3 months
Study: 18025439
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy plus autologous stem-cell transplantation (HDCT)
Study: 11979994
Drug: Therapy for
Normalized name: nutritional therapy for GSD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy for unstable coronary artery disease according to European Society of Cardiology guidelines
Study: 10086546
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg every 6 hours for 5 days)
Study: 1754611
Drug: Bright white-light
Normalized name: Light White Mineral Oil
DrugBank: Light mineral oil (DB11579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright white-light treatment (2,500 lux)
Study: 1754611
Drug: Dim red-light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dim red-light treatment (50 lux)
Study: 7031215
Drug: Three days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three days of nitrofurantoin macrocrystals therapy
Study: 7031215
Drug: Ten days
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ten days of nitrofurantoin macrocrystals therapy
Study: 6094104
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 to 40 mg/day)
Study: 6094104
Drug: Hydrochlorothiazide plus
Normalized name: hydralazine hydrochloride / hydrochlorothiazide Oral Capsule [Hydralazine Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide plus propranolol (50 mg hydrochlorothiazide plus 80 to 240 mg propranolol/day)
Study: 29933749
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) alone
Study: 29933749
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) combined with high-dose aspirin
Study: 19779037
Drug: 15-microg/kg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15-microg/kg bolus followed by a 2-microg/kg/min infusion
Study: 19779037
Drug: 30-microg/kg bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-microg/kg bolus followed by a 4-microg/kg/min infusion
Study: 18822490
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 4 g daily (Group 1)
Study: 18822490
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol in equipotential dose (Group 2)
Study: 18822490
Drug: No paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: No paracetamol (Group 3)
Study: 15677777
Drug: Pioglitazone (monotherapy)
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone (monotherapy)
Study: 15677777
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus sulfonylurea (combination therapy)
Study: 15677777
Drug: Pioglitazone plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone plus metformin (combination therapy)
Study: 15677777
Drug: Metformin (monotherapy)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (monotherapy)
Study: 15677777
Drug: Gliclazide (monotherapy)
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide (monotherapy)
Study: 15677777
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus sulfonylurea (combination therapy)
Study: 15677777
Drug: Gliclazide plus
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliclazide plus metformin (combination therapy)
Study: 2248328
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine (2% dilution in castor oil)
Study: 30027388
Drug: Higher ratings
Normalized name: Aratinga erythrogenys feather extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher ratings of the tobacco treatment care transition
Study: 30027388
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of cessation medication post-discharge
Study: 26924303
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg quercetin
Study: 21067292
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment alone (control group)
Study: 21221773
Drug: Exemestane (EXE)
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane (EXE) 25 mg daily for 12 months
Study: 9971914
Drug: Omeprazole enteric-coated
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole enteric-coated formulation A
Study: 9971914
Drug: Omeprazole enteric-coated
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole enteric-coated formulation B
Study: 2288396
Drug: Flunisolide aerosol
Normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flunisolide aerosol (0.5 mg administered by a jet nebulizer twice daily for 2 months)
Study: 16298736
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) at 1200 or 1800 mg/day
Study: 16298736
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration at 2 l/m for 18 h
Study: 30080128
Drug: Motivational and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motivational and reminder text messages sent twice a week for 3 months
Study: 24521887
Drug: LACJ (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACJ (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + jinghuaweikang gelatin pearls 240 mg, twice daily for 10 days, then jinghuaweikang gelatin pearls 240 mg, twice daily for 14 days)
Study: 24521887
Drug: LACB (lansoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: LACB (lansoprazole 30 mg + amoxicillin 1000 mg + clarithromycin 500 mg + bismuth potassium citrate 220 mg, twice daily for 10 days)
Study: 21248360
Drug: Intra‐esophageal infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra‐esophageal infusion of 5‐mL acidic solution (0.1 N HCl)
Study: 16984212
Drug: Traxoprodil 100mg
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil 100mg oral dose
Study: 16984212
Drug: Traxoprodil 50mg
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil 50mg oral dose
Study: 16984212
Drug: Traxoprodil 300mg
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil 300mg oral dose
Study: 16984212
Drug: Traxoprodil 50mg
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil 50mg intravenous infusion
Study: 16984212
Drug: Traxoprodil 100mg
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil 100mg intravenous infusion
Study: 16984212
Drug: Traxoprodil oral
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil oral administration in poor metabolisers
Study: 16984212
Drug: Traxoprodil oral
Normalized name: Traxoprodil
DrugBank: Traxoprodil (DB18795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traxoprodil oral administration in extensive metabolisers
Study: 8956766
Drug: Control enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control enteral formula (1 L/d for 7 days before surgery)
Study: 8956766
Drug: Enriched enteral
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enriched enteral formula (1 L/d for 7 days before surgery, enriched with arginine, RNA, and omega-3 fatty acids)
Study: 8005921
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Guargum (10 grams) and Acarbose (50 grams)
Study: 8005921
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without trial drugs)
Study: 27717336
Drug: Early enteral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early enteral feeding (first feeding bolus with a polymeric diet (1 kcal/ml) via a feeding tube 3 hours after PEG placement)
Study: 16536766
Drug: Naftopidil 50
Normalized name: Naftopidil
DrugBank: Naftopidil (DB12092)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Naftopidil 50 mg for 4 weeks
Study: 16536766
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg for 4 weeks
Study: 14642684
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg/day for 8 weeks followed by 8 mg/day for 4 weeks)
Study: 9436940
Drug: Interferon alpha
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha (IFN) combined with chemotherapy
Study: 9436940
Drug: IFN maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN maintenance therapy
Study: 3676158
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Fe
Study: 30033619
Drug: FAB 10
Normalized name: digoxin immune FAB 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAB 10 (esomeprazole 20 mg, bismuth 220 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days)
Study: 30033619
Drug: FA 10
Normalized name: IDHIFA 100mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: FA 10 (esomeprazole 20 mg, amoxicillin 1000 mg, furazolidone 100 mg twice daily for 10 days, without bismuth)
Study: 22490404
Drug: Standard antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antithrombotic therapy for two weeks
Study: 20602497
Drug: Postoperative magnesium
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative magnesium hydroxide as a laxative
Study: 20602497
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of laxative and ONS
Study: 8978112
Drug: Current treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current treatment preferences
Study: 4017670
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml of 100-proof vodka per kg of body weight in orange juice
Study: 29804794
Drug: Oral immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral immunotherapy (OIT) with pasteurized raw egg white
Study: 29804794
Drug: IgE specific
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgE specific of ovomucoid titer <2.045kU/l
Study: 24863631
Drug: 10-20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-20 ml/kg FFP (FFP group, n=50)
Study: 24863631
Drug: 10-20 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-20 ml/kg 4% succinylated gelatin (Gelofusine, GEL group, n=50)
Study: 22207015
Drug: Guideline for
Normalized name: LARYNGEAL GUIDEWIRE,PROVOX #7215
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline for initiation and maintenance of insulin infusions for hyperglycemia
Study: 15948160
Drug: RT after
Normalized name: Lotion, Multi Ingredient Topical application Lotion [COPPERTONE SPORT AFTER SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT after the third chemotherapy cycle
Study: 15948160
Drug: RT after
Normalized name: Lotion, Multi Ingredient Topical application Lotion [COPPERTONE SPORT AFTER SUN]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT after the sixth chemotherapy cycle
Study: 15948160
Drug: 1-3 chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 chemotherapy cycles
Study: 8955656
Drug: Dexrazoxane (10:1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexrazoxane (10:1 dose ratio with epirubicin)
Study: 6662683
Drug: azlocillin-gentamicin (AZ-G)
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: azlocillin-gentamicin (AZ-G)
Study: 6662683
Drug: ampicillin-gentamicin (AM-G)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ampicillin-gentamicin (AM-G)
Study: 26888417
Drug: Spirulina supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina supplementation (3 g/day)
Study: 17509103
Drug: Lubiprostone 24
Normalized name: LUBIPROSTONE 24MCG CAP,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lubiprostone 24 mcg/day
Study: 17509103
Drug: Lubiprostone 48
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone 48 mcg/day
Study: 17509103
Drug: Lubiprostone 72
Normalized name: Lubiprostone
DrugBank: Lubiprostone (DB01046)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lubiprostone 72 mcg/day
Study: 16307962
Drug: Drospirenone 3
Normalized name: drospirenone 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drospirenone 3 mg and ethinyl estradiol (EE) 20 mcg
Study: 9701720
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 times daily for 6 days)
Study: 2539180
Drug: Intravenous acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous acyclovir 5 mg kg‐1 t.d.s. for 23 days followed by oral acyclovir 800 mg 6‐hourly for 6 months